5月21日，派格生物医药-B盘中下跌5.14%，报14.41港元，成交额2821.55万港元。该股此前因与腾瑞制药就GLP-1类药物派达康达成中国大陆独家商业化合作，于5月18日尾盘一度飙升超150%，收涨66.31%，5月19日再涨10.91%。
消息面上，双方确立累计销售规模超人民币100亿元的核心商业化目标，腾瑞制药将支付合计约1.4亿港币权益金，派达康近期将在方舟健客互联网医院平台全网首发。经历连续大幅拉升后，该股短期累计涨幅显著，当前成交额较前两日（7.84亿、3.94亿港元）明显萎缩，股价出现技术性回调。同期生物科技板块整体表现偏强，康方生物涨6.87%、荣昌生物涨5.13%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.